{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:32:44Z","timestamp":1770748364806,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82022057 31991171 81830002"],"award-info":[{"award-number":["82022057 31991171 81830002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MedComm"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with relapsed\/refractory classical Hodgkin lymphoma (cHL) achieve complete response (CR) after decitabine\u2010plus\u2010camrelizumab therapy, while long\u2010term outcome especially after treatment discontinuation remains unclear. We present a retrospective analysis of 87 relapsed\/refractory cHL patients who acquired CR after decitabine\u2010plus\u2010camrelizumab. Patients were divided into two groups and received consolidation treatment every 3\u20134 or 6\u201312\u00a0weeks, and 1\u2010year of continuous CR was guaranteed for treatment cessation. At a median follow\u2010up of 5.3 years, the median relapse\u2010free survival (RFS) after achieving CR with decitabine\u2010plus\u2010camrelizumab therapy was 4.5 years, and patients underwent consolidation per 3\u20134\u00a0weeks might have longer RFS. The baseline percentage of peripheral central memory T cells was not associated with RFS, while patients with higher pretreatment serum levels of interleukin\u20106 (IL\u20106) and lactate dehydrogenase (LDH) had significantly shorter RFS and increased risk for disease recurrence. Fifty\u2010seven patients completed and discontinued decitabine\u2010plus\u2010camrelizumab, and their median RFS had not been reached. The 2\u2010year RFS rate after treatment cessation was 78% (95% CI, 67\u201390%). Patients in the high\u2010risk subgroup with higher pretreatment IL\u20106 and LDH levels showed poor treatment\u2010free remission. Moreover, decitabine\u2010plus\u2010camrelizumab therapy was safe and cost\u2010effective. In conclusion, patients who obtained CR with decitabine\u2010plus\u2010camrelizumab and received consolidation per 3\u20134\u00a0weeks can achieve long\u2010term remission after treatment discontinuation.<\/jats:p>","DOI":"10.1002\/mco2.428","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T23:52:49Z","timestamp":1700869969000},"source":"Crossref","is-referenced-by-count":3,"title":["Long\u2010term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine\u2010plus\u2010camrelizumab epi\u2010immunotherapy and treatment cessation"],"prefix":"10.1002","volume":"4","author":[{"given":"Chunmeng","family":"Wang","sequence":"first","affiliation":[{"name":"The Second School of Clinical Medicine Southern Medical University  Guangzhou China"},{"name":"Department of Bio\u2010therapeutic the First Medical Centre, Chinese PLA General Hospital  Beijing China"},{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-7828","authenticated-orcid":false,"given":"Yuting","family":"Pan","sequence":"additional","affiliation":[{"name":"Chinese People's Liberation Army Medical School Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Bio\u2010therapeutic the First Medical Centre, Chinese PLA General Hospital  Beijing China"},{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghua","family":"Rong","sequence":"additional","affiliation":[{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhifang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingming","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Bio\u2010therapeutic the First Medical Centre, Chinese PLA General Hospital  Beijing China"},{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Bio\u2010therapeutic the First Medical Centre, Chinese PLA General Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-3899","authenticated-orcid":false,"given":"Weidong","family":"Han","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medicine Southern Medical University  Guangzhou China"},{"name":"Department of Bio\u2010therapeutic the First Medical Centre, Chinese PLA General Hospital  Beijing China"},{"name":"Department of Bio\u2010therapeutic the Fifth Medical Centre, Chinese PLA General Hospital  Beijing China"},{"name":"Changping Laboratory  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2002322"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1680"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02151"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0939-1"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17849"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1885667"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002347"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0133"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3502.3502"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147881"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03812-w"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt206"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.2020567"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4819-2"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz110"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-841262"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04429-8"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08616.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000678"},{"key":"e_1_2_10_27_1","article-title":"Plasma D\u2010dimer and interleukin\u20106 are associated with treatment response and progression\u2010free survival in advanced NSCLC patients on anti\u2010PD\u20101 therapy","author":"Chen C","year":"2023","journal-title":"Cancer Med\u2010Us"},{"key":"e_1_2_10_28_1","article-title":"Circulating IL\u20106 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti\u2010PD\u20101 therapy","author":"Mirjacic Martinovic K","year":"2023","journal-title":"J Clin Pathol"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.177"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.11.2413.2413"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0030"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7702"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155976"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0118"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"}],"container-title":["MedComm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mco2.428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T10:43:37Z","timestamp":1705488217000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mco2.428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/mco2.428"],"URL":"https:\/\/doi.org\/10.1002\/mco2.428","archive":["Portico"],"relation":{},"ISSN":["2688-2663","2688-2663"],"issn-type":[{"value":"2688-2663","type":"print"},{"value":"2688-2663","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"article-number":"e428"}}